B7-33 represents a breakthrough in relaxin-based research — a simplified, single-chain peptide that captures the anti-fibrotic properties of the complex relaxin hormone. Fibrosis (scarring) is a component of many chronic diseases, making this a broadly relevant research compound.
Research Applications
Anti-fibrotic research, cardiac fibrosis, pulmonary fibrosis, renal fibrosis, and RXFP1 receptor signaling.
Dosage Information (Research Use)
Animal research: varies by model. Subcutaneous administration. Research use only.
Reconstitution & Handling
Standard BAC water reconstitution.
Half-Life & Pharmacokinetics
Not fully characterized.
Reported Observations in Literature
Reduced cardiovascular effects compared to native relaxin. Generally well-tolerated in animal models.
Key Research References
- Hossain MA, et al. “A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor RXFP1.” Chem Sci. 2016